Have You Heard
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending extension of the label for all metformin-containing products to included patients with stable moderate renal failure (chronic kidney disease stage 3).
Dapagliflozin is now recommended by NICE as part of triple therapy with metformin and a sulfonylurea when two drugs for type 2 diabetes are not providing glycaemic control.
In a new Clinical Guideline on multimorbidity, NICE calls for a tailored approach to care when treating people with two or more long-term health conditions. The guideline sets out ways to put patients with complex health issues at the heart of decisions about their care, including how to decide between different medicines and treatments.
NICE has published a new diabetes quality standard for adults featuring seven new and updated statements covering type 2 diabetes prevention, structured education programmes, care and treatment, and prevention and management of foot problems. The new quality standard updates the 2011 version.
The British Heart Foundation has launched the Miles Frost Fund to establish a UK-wide cascade testing service for families at risk of hypertrophic cardiomyopathy (HCM). The fund has been established in memory of Sir David Frost’s son Miles who died suddenly from an undiagnosed heart condition in 2015.
The American Heart Association has published a scientific statement providing prescribers with a list of drugs that can cause or worsen heart failure. Heart failure patients are usually taking medications for multiple medical conditions with resulting risk for drug-drug or drug-condition interactions.